NCT02217930View on ClinicalTrials.gov

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

July 31, 2015

Conditions
Qt Interval, Variation in
Interventions
DRUG

WCK 2349

DRUG

Placebo

DRUG

Moxifloxacin

Trial Locations (1)

53095

Phase 1 unit : Spaulding Clinical Research, LLC, West Bend

Sponsors

Lead Sponsor

Wockhardt
All Listed Sponsors
lead

Wockhardt

INDUSTRY